Bristol’s Bold Projections Grow Bolder As Confidence In R&D Programs Rises
New And Existing Blockbusters Expected To Fill Future Revenue Gaps
Executive Summary
Loss of exclusivity for key Bristol Myers Squibb products, starting with top seller Revlimid, is looming over the company’s R&D pipeline. BMS believes its late-stage and newly approved products will generate more than $25bn in sales by 2029.
You may also be interested in...
BMS Does Not Think Pricing Or Monitoring Will Limit Camzyos Use
Bristol already is training cardiologists at major treatment centers in how to treat obstructive hypertrophic cardiomyopathy with Camzyos (mavacamten) based on the REMS in the US label.
Pfizer’s Big Bet On Arena Pays Off With First Phase III Win For Etrasimod In UC
The company will present detailed data in the future, but top-line results show statistically significant improvement over placebo at 12 weeks in ulcerative colitis, an increasingly competitive market.
Bristol’s Growth Plan Faces First Test In 2022
Zeposia, Reblozyl, Breyanzi and Abecma turned BMS’s new product portfolio into a blockbuster revenue stream last year to help fill the $3.5bn gap created by Revlimid and Abraxane generics.